Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
165Citations signalées, ce qui n’est pas une note de qualité
44Institutions déclarées
1Pays d’affiliation déclarés
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Résumé indisponible. Les résultats de l’étude ne doivent pas être déduits de son seul titre.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
- Date Crossref
- 01/03/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Tongji UniversityShanghai Pulmonary HospitalHunan Cancer HospitalFujian Provincial Cancer HospitalHarbin Medical UniversityThird Affiliated Hospital of Harbin Medical UniversityHebei Medical UniversityFourth Hospital of Hebei Medical UniversityFirst Affiliated Hospital of Henan University of Science and TechnologyShanghai Chest HospitalFirst Affiliated Hospital of Gannan Medical UniversityJilin Province Tumor HospitalShandong Tumor HospitalShandong First Medical UniversityGuangzhou Medical UniversityXuzhou Medical CollegeQingdao UniversityAffiliated Hospital of Qingdao UniversityChinese People's Liberation ArmyGuangxi Medical UniversityFirst Affiliated Hospital of GuangXi Medical UniversityHenan Cancer HospitalPeking UniversityPeking University First HospitalFirst Affiliated Hospital of Zhengzhou UniversityZhejiang Cancer HospitalFirst Affiliated Hospital of Xinxiang Medical UniversityTianjin Chest HospitalFirst Affiliated Hospital of University of South ChinaUniversity of South ChinaTongji HospitalHuazhong University of Science and TechnologyAnhui Medical UniversityFirst Affiliated Hospital of Anhui Medical UniversityTianjin Medical University Cancer Institute and HospitalFirst Affiliated Hospital of Guangzhou Medical UniversityShanghai East HospitalArmy Medical UniversityDaping HospitalChangsha Central HospitalCentral South UniversityThird Xiangya HospitalAffiliated Hospital of Hebei UniversityAnhui Provincial Hospital
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Les sujets associés
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsPeptidase Inhibition and Analysis